BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pawlotsky J, Ramers CB, Dillon JF, Feld JJ, Lazarus JV. Simplification of Care for Chronic Hepatitis C Virus Infection. Semin Liver Dis 2020;40:392-402. [DOI: 10.1055/s-0040-1713657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Zajkowska M, Mroczko B. Chemokines in Primary Liver Cancer. IJMS 2022;23:8846. [DOI: 10.3390/ijms23168846] [Reference Citation Analysis]
2 Cabezas J, Llerena S, Mateo M, Álvarez R, Cobo C, González V, Martró E, Cuadrado A, Crespo J. Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentences. Diagnostics (Basel) 2021;11:877. [PMID: 34068955 DOI: 10.3390/diagnostics11050877] [Reference Citation Analysis]
3 Rojas SA, Godino JG, Northrup A, Khasira M, Tam A, Asmus L, Frenette C, Ramers CB. Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center. Hepatol Commun 2021;5:412-23. [PMID: 33681676 DOI: 10.1002/hep4.1617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Shahid I, Alzahrani AR, Al-Ghamdi SS, Alanazi IM, Rehman S, Hassan S. Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises. Diagnostics (Basel) 2021;11:1253. [PMID: 34359335 DOI: 10.3390/diagnostics11071253] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
5 de Mattos ÂZ, Debes JD, Boonstra A, Yang JD, Balderramo DC, Sartori GDP, de Mattos AA. Current impact of viral hepatitis on liver cancer development: The challenge remains. World J Gastroenterol 2021; 27(24): 3556-3567 [PMID: 34239269 DOI: 10.3748/wjg.v27.i24.3556] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Sims OT, Truong DN, Wang K, Melton PA, Atim K. Time to HCV Treatment Disfavors Patients Living with HIV/HCV Co-infection: Findings from a Large Urban Tertiary Center. J Racial Ethn Health Disparities 2021. [PMID: 34254269 DOI: 10.1007/s40615-021-01105-5] [Reference Citation Analysis]
7 Gane E, de Ledinghen V, Dylla DE, Rizzardini G, Shiffman ML, Barclay ST, Calleja JL, Xue Z, Burroughs M, Gutierrez JA. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. J Viral Hepat 2021;28:1635-42. [PMID: 34448313 DOI: 10.1111/jvh.13600] [Reference Citation Analysis]
8 Chang TS, Chang KC, Chen WM, Hsu NT, Lee CY, Lin YC, Huang WC, Chiu WN, Hu JH, Huang TJ, Chen MY, Lu SN. Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study. BMJ Open 2021;11:e046115. [PMID: 34233977 DOI: 10.1136/bmjopen-2020-046115] [Reference Citation Analysis]